ADAMTS13 (von Willebrand factor-cleaving protease)
ADAMTS13 (von Willebrand factor-cleaving protease)
Specimen Profile
Key information about this biospecimen.
About ADAMTS13 (von Willebrand factor-cleaving protease)
Human biospecimens for projects involving ADAMTS13 (von Willebrand factor-cleaving protease).
Sourcing Options
Reliable sourcing network and project-based documentation.
Standard Samples
Current sourceable options can be checked against your specification.
Bulk Supply
Bulk-volume sourcing may be available depending on marker, matrix and project requirements.
Custom / Prospective Collection
For projects requiring defined donor, matrix or collection criteria.
Matched / Paired Samples
Matched or longitudinal sets (e.g. disease/healthy, pre/post) can be discussed where feasible.
Define Your Requirement
Tell us the specification you need. Our team will check current sourcing options for you.
Not sure about the specification?
Our technical team can help you define the most suitable matrix, titre range, donor profile or other project requirements.
Your information will only be used for this inquiry and handled in confidence.
Sourcing & Documentation
Overseas sourcing route available
We work with trusted international partners to source high-quality biospecimens.
Source verification
Source and specification are confirmed for each project.
Documentation available by project
Supporting documentation may include matrix details, donor/cohort information, test-related or characterization information where applicable.
Supporting documentation is confirmed according to the current source and project requirements.
Intended Use & Compliance
For Research & IVD Development Use
Human biospecimens are supplied for research and IVD development purposes and are not intended for direct human use. Availability and China import eligibility are reviewed based on specimen type, source, intended use and project requirements.
Partner with XIAOPROTEIN
Need a Different Specification?
Looking for another matrix, titre range, donor profile or collection requirement? Tell us what you need.
Marker / Disease Cohort
ADAMTS13 (von Willebrand factor-cleaving protease)
Matrix Options
Plasma
Overview
What is this product?
ADAMTS13-characterized specimen cohort for TTP/ADAMTS13 activity or inhibitor-assay development and validation.
Severe ADAMTS13 deficiency is a key laboratory feature in immune thrombotic thrombocytopenic purpura. Activity, inhibitor/antibody status, timing relative to plasma therapy and assay method are important. Matrix option(s): Plasma. For assay development or validation, confirm the exact cohort/analyte definition, collection timing, handling conditions, lot availability and project-specific use restrictions.
Specimen Considerations
Sample handling considerations
Matrix option(s): Plasma. Confirm specimen type/anticoagulant, collection timing, donor phenotype or disease definition, analyte positivity/level where relevant, freeze–thaw history, volume, treatment status and assay-specific acceptance criteria.
Technical Characteristics
Sample Information
Marker / Disease Cohort
ADAMTS13 (von Willebrand factor-cleaving protease)
Disease Areas
Miscellaneous
Matrix
Plasma
Application Workflow
Sample position in workflow
Collection
Characterization
Validation